October 17, 2019

Peterson, Roden honored for translational medicine efforts

Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics.

 

by Bill Snyder

Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics. They will be honored during ASCPT’s 2020 Annual Meeting March 18-21 in Houston.

Josh Peterson, MD, MPH

Both Peterson and Roden are leaders in PREDICT, a personalized medicine initiative at Vanderbilt University Medical Center that since 2010 has applied genomic testing to drug prescribing in an effort to avoid adverse drug reactions.

Peterson, associate professor of Biomedical Informatics and Medicine in the Vanderbilt University School of Medicine, will receive the society’s Malle Jurima-Romet Mid-Career Leadership Award, named for the late Malle Jurima-Romet, PhD, senior director of Drug Development at the global clinical research services company Celerion.

In addition to his contributions to pharmacogenomics and clinical informatics, Peterson directs the Master of Science in Applied Clinical Informatics program.

Dan Roden, MD

Roden, Senior Vice President for Personalized Medicine at VUMC and holder of the endowed Sam L. Clark, MD, PhD Chair in the School of Medicine, is the recipient of the Oscar B. Hunter Career Award in Therapeutics, named for the famed George Washington University pathologist. Internationally known for his contributions to understanding how genetic variation affects drug response, Roden also is professor of Medicine, Biomedical Informatics and Pharmacology. One of his major research interests is pharmacogenomics — especially the role genetic variations play in adverse drug reactions such as drug-induced arrhythmias.

“The Hunter award has been given annually since 1955 for a ‘meritorious career’ in drug research, patient care and teaching,” Roden said. “Jonas Salk received the first award, and the list of recipients includes leaders in translational medicine. I am deeply honored to be included among such amazing company.”